Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Quest Diagnostics reported second quarter 2026 results characterized by robust top-line growth and improved profitability driven by increased demand across multiple customer channels, including physicians, hospitals, and consumers.</li><li>The company generated consolidated revenues of $3.04 billion, reflecting a 10.2% year-over-year increase, with organic revenue growth also at 10%.</li><li>This growth was fueled by higher volume, particularly from collaborations with Corewell Health and Fresenius Medical Care, which contributed significantly to volume expansion.</li></ul>

Quest Diagnostics reported second quarter 2026 results characterized by robust top-line growth and improved profitability driven by increased demand across multiple customer channels, including physicians, hospitals, and consumers.The company generated consolidated revenues of $3.04 billion, reflecting a 10.2% year-over-year increase, with organic revenue growth also at 10%.This growth was fueled by higher volume, particularly from collaborations with Corewell Health and Fresenius Medical Care, which contributed significantly to volume expansion.

Quest Diagnostics Unlocks Growth With Corewell Health And Fresenius; But Will It Last?

<ul><li>Quest Diagnostics Incorporated reported a solid start to fiscal year 2026, driven by organic revenue growth and operational improvements.</li><li>The company delivered consolidated revenues of $2.9 billion in the first quarter, representing a 9.2% increase year-over-year, with organic growth contributing approximately 9%.</li><li>Volume growth was robust at 10.9%, with major contributions from partnerships with Fresenius Medical Care and Corewell Health that accounted for about 7% of the growth.</li></ul>

Quest Diagnostics Incorporated reported a solid start to fiscal year 2026, driven by organic revenue growth and operational improvements.The company delivered consolidated revenues of $2.9 billion in the first quarter, representing a 9.2% increase year-over-year, with organic growth contributing approximately 9%.Volume growth was robust at 10.9%, with major contributions from partnerships with Fresenius Medical Care and Corewell Health that accounted for about 7% of the growth.

<ul><li>Quest Diagnostics reported a robust financial performance for the fourth quarter and full-year 2025, achieving double-digit growth in both revenues and earnings per share.</li><li>The company attributed its success to strategic execution, including the expansion of clinical innovations, strategic collaborations, and increased market presence in diagnostics and wellness.</li><li>Quest Diagnostics continues to enhance operational efficiency through automation, AI, and streamlined processes, which have contributed to productivity gains and cost savings.</li></ul>

Quest Diagnostics reported a robust financial performance for the fourth quarter and full-year 2025, achieving double-digit growth in both revenues and earnings per share.The company attributed its success to strategic execution, including the expansion of clinical innovations, strategic collaborations, and increased market presence in diagnostics and wellness.Quest Diagnostics continues to enhance operational efficiency through automation, AI, and streamlined processes, which have contributed to productivity gains and cost savings.

Quest Diagnostics’ Margin Story Is Just Getting Started—Why Partnerships Are the Hidden Lever!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

<ul><li>Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the previous year.</li><li>This growth was driven by a combination of organic expansion, contributions from acquisitions, and increased demand for the company's clinical solutions.</li><li>Organic revenue grew 6.8%, indicating positive momentum in the company's core operations.</li></ul>

Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the previous year.This growth was driven by a combination of organic expansion, contributions from acquisitions, and increased demand for the company's clinical solutions.Organic revenue grew 6.8%, indicating positive momentum in the company's core operations.

Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!

United States

Quest Diagnostics Incorporated provides diagnostic testing, information, and services.  The Company operates a national network of full-service laboratories, rapid response laboratories, and patient service centers.  Quest Diagnostics provides esoteric testing, routine medical testing, drugs of abuse testing, and non-hospital-based anatomicpathology testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Quest Diagnostics (DGX US)

Quest Diagnostics Unlocks Growth With Corewell Health And Fresenius; But Will It Last?

Quest Diagnostics reported second quarter 2026 results characterized by robust top-line growth and improved profitability driven by increased...

Baptista Research

Quest Diagnostics: Wearables Strategy

Quest Diagnostics Incorporated reported a solid start to fiscal year 2026, driven by organic revenue growth and operational improvements. The...

Baptista Research

Quest Diagnostics’ Margin Story Is Just Getting Started—Why Partnerships Are the Hidden Lever!

Quest Diagnostics reported a robust financial performance for the fourth quarter and full-year 2025, achieving double-digit growth in both...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!

Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)